Clinical Trial Search

Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants

Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…

Primary: Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for…

Primary: Complete Remission Rate — 8; 6 Participants

Primary: Progression-Free Survival (PFS) — 73 percentage of participants

Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients

Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…

Primary: Day 100 TRM — 4 Participants

Primary: Number of Participants Who Experienced Transplant Related Mortality — 5; 4 Participants

Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035

Primary: Complete Remission — 10 participants

Primary: Survival at 1 Year After Transplantation — 10; 6 participants

Primary: Transplant Related Mortality Rate — 1; 6 Participants

Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…

Primary: Composite Success Rate — 100; 75; 84 Percentage of participants

Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants

Primary: Safety of DLI Following a Non-myeloablative Transplant, Defined as Incidence of Grade IV Acute GVHD — 5.7 percentage of participants

Primary: Number of Participants With Absolute Neutrophil Count >= 500/Mcl for 3 Consecutive Measurements on Different Days and Platelet Count > 20,000/mm^3 With no Platelet…

Primary: Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA) — 19; 6; 0; 0 participants

Primary: Number of Patients Who Obtain Partial Response/Complete Remission — 1; 5 Participants

Primary: Number of Subjects With Study Related Adverse Events. — 59 Participants

Primary: Proportion of Patients With CNS Involvement by B-cell NHL, Relapsed PCNSL, or Relapsed PIOL Who Are Alive and Progression-free at One Year — 28 Participants

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Overall Survival at 1 Year — 90 percentage of participants

Primary: Percentage of Participants With Progression Free Survival (PFS) — 35.0; 41.1 percentage of participants — p=0.4092

Primary: Overall Survival — 79; 49 Participants

Primary: Disease-free Survival — 76; 88; 70 percentage of participant

Primary: Grades of Toxicity by Type of Toxicity — 2; 2; 1; 1 toxicities

Primary: Overall Survival at 6 Months Post-transplant in Patients Receiving a Partially-matched Related Donor Allogeneic Transplant After Reduced-intensity Conditioning — 22…

Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events